These mutations, which result in hematopoietic and developmental abnormalities [40, 59, 87, 88, 89, 90, 91, 92, 93, 94], account for 25% of all DBA patients [10, 79, 82] and illustrate the significance of eS19, the protein coded by the RPS19 gene. This evidence concerns the gene RPS19 and Diamond-Blackfan anemia.